Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer

Representing 15% to 20% of all invasive breast cancers, adjuvant systemic treatment for early-stage, high-risk triple-negative breast cancer (TNBC) is preferentially done in the neoadjuvant setting based on a chemotherapy backbone of anthracyclines and taxanes. Pathological complete response to neoa...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, Diogo, Mesquita, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243491/
https://www.ncbi.nlm.nih.gov/pubmed/35783596
http://dx.doi.org/10.1177/11782234221107580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243491/
https://www.ncbi.nlm.nih.gov/pubmed/35783596
http://dx.doi.org/10.1177/11782234221107580

Ejemplares similares